People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension ...

Generalised myasthenia gravis (gMG) is a chronic disorder in which the body's immune system mistakenly targets the neuromuscular junctions—areas where nerves signal muscles to move. This ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...